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Abstract: Background
Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales
(ESBL-E) among hospitalized neonates in sub-Saharan Africa pose significant clinical
challenges. However, sources of infection and risk factors for transmission are not
clearly defined in this setting.
Methods
In a cohort study of consecutive neonatal admissions to Kilifi County Hospital (KCH)
from July 2013-August 2014, we estimated ESBL-E carriage prevalence on admission
using rectal swab cultures and identified risk factors using logistic regression. Using
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
twice-weekly follow up swabs, we estimated the incidence and identified risk factors for
ESBL-E acquisition in hospital using Poisson regression.
Results
The prevalence of ESBL-E carriage at admission was 10% (59/569). Caesarean
section delivery, older neonatal age, and smaller household size were significant risk
factors. Of the 510 infants admitted without ESBL-E carriage, 238 (55%) acquired
carriage during their hospital stay. The incidence of acquisition was 21.4% (95% CI
19.0, 24.0) per day. The rate was positively associated with the number of known
neonatal ESBL-E carriers and with the total number of neonates on the same ward.
Conclusions
Carriage of ESBL-E was common among neonates on admission and acquisition in
hospital was rapid. The dissemination and selection of ESBL-E appears to be driven by
hospital exposures; operative delivery and neonatal ward patient density. Further
attention to infection control, patient crowding and carriage surveillance is warranted.
Response to Reviewers: Response to reviewer 1:
A very clear and well written manuscript highlighting the rapidity of acquisition of ESBL
coliforms in hospitalized neonates. It will be of interest to paediatric infection specialists
and neonatologists.
I have a few minor technical queries / comments on the methods:
- Can the authors include the year / version number of the CLSI guidelines in the text
for clarity.
Response: We used the CLSI guideline for the year 2014 and reference to it was
overlooked during writing up the manuscript. We have updated this in the text and
references.
- The method for detection of ESBL in Enterobacter needs clarification since this genus
is not included in the CLSI guidance and the presence of AmpC complicates things.
Response: The reviewer is correct; phenotypic ESBL testing is problematic for
Enterobacter species due to AmpC beta-lactamase production. We have described the
limitation of our methods in terms of Enterobacter species that may give false negative
results in phenotypic ESBL testing in the discussion as follows:
“Our prevalence and incidence estimates may also be underestimates since stool
culture may be more sensitive than rectal swab culture, a single sample is less
sensitive than multiple samples for culture and some Enterobacter spp, which are
known to produce AmpC beta-lactamases, may have tested falsely-negative for ESBL
by the phenotypic method used.”
We do have whole-genome sequencing data for 19 Enterobacter species from this
study, that were ESBL positive using the CLSI phenotypic assay for E. coli and K.
pneumoniae, and can report that all of them possessed bla CTX-M-15 in addition to an
AmpC cephalosporinase.
- Please provide a definition of "multi-drug resistant" (results line 172).
Response: We defined multi-drug resistance as resistance to at least one agent in
three or more antimicrobial categories as recommended by Magiorakos et al. 2012.
- I am not a statistician but am aware of the problems of over-dispersion in Poisson
regression modelling: was this checked for?
Response: The reviewer is correct that over dispersion is sometimes an issue when
using Poisson models. It arises, for example, when there are multiple events per
person and heterogeneity between individuals in the rate of acquisition. Under these
circumstances the variability in the number of events per person is greater than that
predicted by the Poisson model (i.e., the data are over-dispersed relative to the
Poisson distribution). However, our analysis is different because we modelled time to
first acquisition (i.e., maximum of 1 event per person). In this situation it is impossible
to identify heterogeneity and hence over-dispersion does not play a role.
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The results in Tables 2 and 3 is duplicated in the supplementary tables: would it be
possible just include just once?
Response: Thank you for this excellent suggestion. We have removed Table 2 and 3
and replaced the two tables with supplementary tables S2 and S3 in the main text.
Response to reviewer 2:
This very interesting study by Dr. Kangia and colleagues focuses on ESBL-E
colonization in hospitalized neonates and, in particular, on sources of infection and risk
factors for transmission.
Although the data were collected between 2013-2014 in only one rural Kenyan hospital
this paper provides very useful and relevant information, specifically providing
incidence data on acquisition of ESBL in hospitalized neonates.
*This topic is relevant for clinical practice because despite the fact that these infections
often have a poor outcome, the epidemiology of transmission is poorly characterized.
There is some evidence of hospital-acquired carriage in older children but this is the
first study investigating the sequential rate of acquisition of ESBL-E carriage in hospital
over time. Previous studies have collected data at admission and discharge only.
**This study is a prospective study estimating ESBL-E carriage prevalence from rectal
swab with a robust systematic approach (day 0, 2, 4, 6, and twice weekly thereafter
until an ESBL-E was isolated or until hospital discharge or death, whichever came
first). In addition to the epidemiological and clinical data, the number of neonates in
each room, bed-location and antimicrobial use of all participants was recorded daily.
This study reveals that among neonates admitted, 10% were already carriers of ESBL-
E. Interestingly, the authors showed how the incidence of ESBL-E acquisition was 21.4
(95% CI 19.0, 24.0) per 100 child days of observation, and the median time to
acquisition among these patients was 3 (IQR 1-5) inpatient days.  This data provides a
reasonably robust baseline to assist in the design and conduct of future IPC/ASP
interventional trials.
The Authors' findings suggest that the greatest risk factors for ESBL-E acquisition in
hospital are the increased numbers of existing ESBL-E carriers among neonatal
patients and hospital crowding. Although it may seem intuitive, only few studies
currently support this. Interestingly, Authors' findings suggest a threshold effect where
risk plateaued after admitting more that 10-14 neonates in a ward. It would be useful to
reference the recent paper by Smit et al in the discussion of the complexity of gene
transfer ( Smit PW, Stoesser N, Pol S, et al. Transmission Dynamics of Hyper-Endemic
Multi-Drug Resistant Klebsiella pneumoniae in a Southeast Asian Neonatal Unit: A
Longitudinal Study With Whole Genome Sequencing. Front Microbiol. 2018 Jun
5;9:1197. doi: 10.3389/fmicb.2018.01197. eCollection 2018. PubMed PMID: 29951041.
Response: Thank you for this suggestion, it is a very interesting paper. We have
included it in the discussion as follows:
“A study in Cambodia of transmission of third-generation cephalosporin-resistant
Klebsiella pneumoniae isolates in a newly opened neonatal unit found that most
clusters were likely to have been due to patient sources while 2 of 9 clusters could
have been due to either an environmental or a patient source.”
In this study 93% of neonates were receiving antibiotics during hospitalization and this,
of course, underpowered the observation of any differences.  The Authors state:
"specifically use of third generation cephalosporins during the inpatient stay was not
shown to be correlated with ESBL-E acquisition". It would be very interesting to know
what proportion of the neonates were on ampicillin and gentamicin or third generation
cephalosporins and whether there was any difference between the regimens.
Response: Table 2 provides data on how many neonates received different antibiotic
regimens among those who were admitted with ESBL-E carriage. 455/510 (89%)
neonates received ampicillin and gentamicin and 116/510 (23%) received a third-
generation cephalosporin.
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The other major question is whether there is in fact higher rates of carriage of ESBL-E
populations on admission, but as this is low level colonization they are not identified as
plated colonies. After exposure with antibiotics, the non-ESBL organisms are selected
out, and then much higher rates of ESBL containing colonies are identified on the
plates. Can the authors comment on whether ESBL-E carriage could in fact be the
same on admission and discharge and the apparent acquisition is an artifact of
antibiotic selection and sub-culture methods.
Response: This is an interesting suggestion and we have added it into the discussion.
While it is certainly possible that low-level ESBL-E carriage, below detection rate by
culture methods, is amplified by selection pressure from the use of antibiotics until it is
detectable, we do not think it is likely that this accounts for the entire effect seen in the
study. Certainly, the association we saw between age at admission and carriage at
admission would not be explained by antibiotic use. We have included this possibility in
the discussion as follows:
“It is theoretically possible that low-level ESBL-E carriage was more prevalent at
admission than we were able to determine; below detection rate by culture methods,
but then amplified by selection pressure from the use of antibiotics in hospital until
detectable.”
Is there any chance to retrieve information on resistance patterns for different post
natal ages? Although these are low numbers, it would be interesting to determine
whether resistance phenotype can be used to assist in differentiating community and
hospital based ESBL-E acquisition (see Blackburn et al (Epidemiol Infect. 2014
Apr;142(4):803-11. doi: 10.1017/S0950268813001520. Epub 2013 Jul 11.)
Response: Thank you for this suggestion. Unfortunately, we observed no difference in
the antibiotic sensitivity profile from ESBL-E carriage isolates among neonates of
different ages.
Overall the manuscript will benefit from only minor revisions:
Abstract needs some re-writing as it doesn't do justice to the study.
For example, the sentence " However, sources of infection and risk factors for
transmission are not clearly defined in this setting" does not clearly define what the
Authors are going to present.
Response: We have rewritten this section as suggested:
“Data on prevalence and acquisition of ESBL-E carriage among hospitalized neonates
in the region are few and risk factors for transmission are not clearly defined.”
Materials and Methods section
It would be helpful to have a summary in the text (instead of in table TS1) of the
exclusion criteria for this study.
Response: All neonatal admissions during the study period were eligible to be recruited
in the study. We state in the methods “Neonatal admissions were eligible for
recruitment into the study if they were admitted to the High Dependency Unit (HDU)
between 1st July 2013 and 29th August 2014 or to the neonatal rooms in the general
pediatric ward between 16th August 2013 and 29th August 2014.” In addition, we
describe the important differences between eligible included neonates and excluded
neonates in the discussion as follows: “Of note, significantly more parents/guardians of
older neonates, and neonates born in hospital by caesarean section, declined to
participate in the study (Supplementary table S1)”
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15th October, 2018. 
 
Dear Dr. Kathryn M. Edwards, 
Associate Editor, 
Clinical Infectious Diseases, 
198 Madison Ave 
New York NY 10016. 
 
RE: Submission of revised manuscript CID-91249. 
 
Thank you for your email dated 16th August 2018 enclosing reviewers comments.  
 
We have carefully reviewed the comments and revised the manuscript accordingly. Our 
responses are given in a point by point manner below. We have also attached a manuscript 
copy with tracked changes and a clean one for review. 
 
I hope that the changes we have made will resolve your concerns. We are more than happy to 
make further changes that will improve the paper and facilitate successful publication in your 
journal. 
 
Thank you for your time and interest in our work and we are looking forward to hearing from 
you in due course. 
 
 
Yours sincerely, 
Ngure Kagia. 
 
 
Response to reviewer 1:  
Cover Letter Click here to access/download;Cover
Letter;Cover_Letter_to_Editor_2.ngk.docx
 A very clear and well written manuscript highlighting the rapidity of acquisition of ESBL 
coliforms in hospitalized neonates. It will be of interest to paediatric infection specialists and 
neonatologists. 
 
I have a few minor technical queries / comments on the methods: 
- Can the authors include the year / version number of the CLSI guidelines in the text for clarity. 
 
Response: We used the CLSI guideline for the year 2014 and reference to it was overlooked 
during writing up the manuscript. We have updated this in the text and references. 
 
- The method for detection of ESBL in Enterobacter needs clarification since this genus is not 
included in the CLSI guidance and the presence of AmpC complicates things. 
Response: The reviewer is correct; phenotypic ESBL testing is problematic for Enterobacter 
species due to AmpC beta-lactamase production. We have described the limitation of our 
methods in terms of Enterobacter species that may give false negative results in phenotypic 
ESBL testing in the discussion as follows:  
“Our prevalence and incidence estimates may also be underestimates since stool culture may 
be more sensitive than rectal swab culture, a single sample is less sensitive than multiple 
samples for culture and some Enterobacter spp, which are known to produce AmpC beta-
lactamases, may have tested falsely-negative for ESBL by the phenotypic method used.” 
We do have whole-genome sequencing data for 19 Enterobacter species from this study, that 
were ESBL positive using the CLSI phenotypic assay for E. coli and K. pneumoniae, and can 
report that all of them possessed bla CTX-M-15 in addition to an AmpC cephalosporinase. 
 
- Please provide a definition of "multi-drug resistant" (results line 172). 
 
Response: We defined multi-drug resistance as resistance to at least one agent in three or more 
antimicrobial categories as recommended by Magiorakos et al. 2012. 
 - I am not a statistician but am aware of the problems of over-dispersion in Poisson regression 
modelling: was this checked for? 
 
Response: The reviewer is correct that over dispersion is sometimes an issue when using 
Poisson models. It arises, for example, when there are multiple events per person and 
heterogeneity between individuals in the rate of acquisition. Under these circumstances the 
variability in the number of events per person is greater than that predicted by the Poisson 
model (i.e., the data are over-dispersed relative to the Poisson distribution). However, our 
analysis is different because we modelled time to first acquisition (i.e., maximum of 1 event per 
person). In this situation it is impossible to identify heterogeneity and hence over-dispersion 
does not play a role. 
  
 
 
The results in Tables 2 and 3 is duplicated in the supplementary tables: would it be possible just 
include just once? 
 
Response: Thank you for this excellent suggestion. We have removed Table 2 and 3 and 
replaced the two tables with supplementary tables S2 and S3 in the main text. 
 
 
Response to reviewer 2:  
This very interesting study by Dr. Kangia and colleagues focuses on ESBL-E colonization in 
hospitalized neonates and, in particular, on sources of infection and risk factors for 
transmission. 
 
Although the data were collected between 2013-2014 in only one rural Kenyan hospital this 
paper provides very useful and relevant information, specifically providing incidence data on 
acquisition of ESBL in hospitalized neonates. 
*This topic is relevant for clinical practice because despite the fact that these infections often 
have a poor outcome, the epidemiology of transmission is poorly characterized. There is some 
evidence of hospital-acquired carriage in older children but this is the first study investigating 
the sequential rate of acquisition of ESBL-E carriage in hospital over time. Previous studies have 
collected data at admission and discharge only. 
**This study is a prospective study estimating ESBL-E carriage prevalence from rectal swab with 
a robust systematic approach (day 0, 2, 4, 6, and twice weekly thereafter until an ESBL-E was 
isolated or until hospital discharge or death, whichever came first). In addition to the 
epidemiological and clinical data, the number of neonates in each room, bed-location and 
antimicrobial use of all participants was recorded daily. 
 
This study reveals that among neonates admitted, 10% were already carriers of ESBL-E. 
Interestingly, the authors showed how the incidence of ESBL-E acquisition was 21.4 (95% CI 
19.0, 24.0) per 100 child days of observation, and the median time to acquisition among these 
patients was 3 (IQR 1-5) inpatient days.  This data provides a reasonably robust baseline to 
assist in the design and conduct of future IPC/ASP interventional trials. 
 
The Authors' findings suggest that the greatest risk factors for ESBL-E acquisition in hospital are 
the increased numbers of existing ESBL-E carriers among neonatal patients and hospital 
crowding. Although it may seem intuitive, only few studies currently support this. Interestingly, 
Authors' findings suggest a threshold effect where risk plateaued after admitting more that 10-
14 neonates in a ward. It would be useful to reference the recent paper by Smit et al in the 
discussion of the complexity of gene transfer ( Smit PW, Stoesser N, Pol S, et al. Transmission 
Dynamics of Hyper-Endemic Multi-Drug Resistant Klebsiella pneumoniae in a Southeast Asian 
Neonatal Unit: A Longitudinal Study With Whole Genome Sequencing. Front Microbiol. 2018 
Jun 5;9:1197. doi: 10.3389/fmicb.2018.01197. eCollection 2018. PubMed PMID: 29951041.  
Response: Thank you for this suggestion, it is a very interesting paper. We have included it in 
the discussion as follows: 
“A study in Cambodia of transmission of third-generation cephalosporin-resistant Klebsiella 
pneumoniae isolates in a newly opened neonatal unit found that most clusters were likely to 
have been due to patient sources while 2 of 9 clusters could have been due to either an 
environmental or a patient source.” 
 
In this study 93% of neonates were receiving antibiotics during hospitalization and this, of 
course, underpowered the observation of any differences.  The Authors state: "specifically use 
of third generation cephalosporins during the inpatient stay was not shown to be correlated 
with ESBL-E acquisition". It would be very interesting to know what proportion of the neonates 
were on ampicillin and gentamicin or third generation cephalosporins and whether there was 
any difference between the regimens. 
 
Response: Table 2 provides data on how many neonates received different antibiotic regimens 
among those who were admitted with ESBL-E carriage. 455/510 (89%) neonates received 
ampicillin and gentamicin and 116/510 (23%) received a third-generation cephalosporin. 
 
The other major question is whether there is in fact higher rates of carriage of ESBL-E 
populations on admission, but as this is low level colonization they are not identified as plated 
colonies. After exposure with antibiotics, the non-ESBL organisms are selected out, and then 
much higher rates of ESBL containing colonies are identified on the plates. Can the authors 
comment on whether ESBL-E carriage could in fact be the same on admission and discharge and 
the apparent acquisition is an artifact of antibiotic selection and sub-culture methods. 
 
Response: This is an interesting suggestion and we have added it into the discussion. While it is 
certainly possible that low-level ESBL-E carriage, below detection rate by culture methods, is 
amplified by selection pressure from the use of antibiotics until it is detectable, we do not think 
it is likely that this accounts for the entire effect seen in the study. Certainly, the association we 
saw between age at admission and carriage at admission would not be explained by antibiotic 
use. We have included this possibility in the discussion as follows: 
“It is theoretically possible that low-level ESBL-E carriage was more prevalent at admission than 
we were able to determine; below detection rate by culture methods, but then amplified by 
selection pressure from the use of antibiotics in hospital until detectable.” 
 
 
Is there any chance to retrieve information on resistance patterns for different post natal ages? 
Although these are low numbers, it would be interesting to determine whether resistance 
phenotype can be used to assist in differentiating community and hospital based ESBL-E 
acquisition (see Blackburn et al (Epidemiol Infect. 2014 Apr;142(4):803-11. doi: 
10.1017/S0950268813001520. Epub 2013 Jul 11.)  
 
Response: Thank you for this suggestion. Unfortunately, we observed no difference in the 
antibiotic sensitivity profile from ESBL-E carriage isolates among neonates of different ages. 
 
Overall the manuscript will benefit from only minor revisions: 
 
Abstract needs some re-writing as it doesn't do justice to the study. 
For example, the sentence " However, sources of infection and risk factors for transmission are 
not clearly defined in this setting" does not clearly define what the Authors are going to 
present. 
 
Response: We have rewritten this section as suggested: 
“Data on prevalence and acquisition of ESBL-E carriage among hospitalized neonates in the 
region are few and risk factors for transmission are not clearly defined.” 
 
Materials and Methods section 
It would be helpful to have a summary in the text (instead of in table TS1) of the exclusion 
criteria for this study. 
 
Response: All neonatal admissions during the study period were eligible to be recruited in the 
study. We state in the methods “Neonatal admissions were eligible for recruitment into the 
study if they were admitted to the High Dependency Unit (HDU) between 1st July 2013 and 29th 
August 2014 or to the neonatal rooms in the general pediatric ward between 16th August 2013 
and 29th August 2014.” In addition, we describe the important differences between eligible 
included neonates and excluded neonates in the discussion as follows: “Of note, significantly 
more parents/guardians of older neonates, and neonates born in hospital by caesarean section, 
declined to participate in the study (Supplementary table S1)” 
 
 
 
 
 1 
Carriage and acquisition of Extended Spectrum Beta-Lactamase producing 1 
Enterobacterales among neonates admitted to hospital in Kilifi, Kenya 2 
 3 
Ngure Kagia1*, Patrick Kosgei1, Michael Ooko1, Leonard Wafula1, Neema Mturi1, Kirimi Anampiu1, 4 
Salim Mwarumba1, Patricia Njuguna1, Anna C. Seale1,2,3, James A. Berkley1, 2, Christian 5 
Bottomley3, J. Anthony G. Scott1, 3, Susan C. Morpeth1, 3, 4 6 
 7 
Affiliations 8 
1. KEMRI- Wellcome Trust Research Programme, CGMR-Coast, Kilifi, Kenya 9 
2. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK 10 
3. Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical 11 
Medicine, London, UK  12 
4. Counties Manukau District Health Board, Auckland, New Zealand 13 
 14 
Keywords 15 
Neonates, Extended Spectrum Beta-Lactamase, Carriage, Acquisition, Risk-factors 16 
Running title  17 
Risk factors of carriage and rapid nosocomial acquisition of Extended Spectrum Beta-Lactamase 18 
producing Enterobacterales amongst neonates admitted to hospital in Kilifi, Kenya 19 
 20 
Corresponding author* 21 
 22 
We report a prospective hospital-based longitudinal study that estimates the ESBL-E carriage 23 
prevalence among neonates on admission, the incidence of acquisition of ESBL-E carriage in 24 
hospital and the risk factors for neonatal prevalent and incident ESBL-E carriage. 25 
  26 
Full Manuscript in .doc format only [no PDFs] Click here to access/download;Full Manuscript in .doc format
only [no PDFs];CID-91249_revised.docx
 2 
ABSTRACT 27 
 28 
Background 29 
Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) 30 
among hospitalized neonates in sub-Saharan Africa pose significant clinical challenges. Data on 31 
prevalence and acquisition of ESBL-E carriage among hospitalized neonates in the region are 32 
few and risk factors for transmission are not clearly defined. 33 
Methods  34 
In a cohort study of consecutive neonatal admissions to Kilifi County Hospital (KCH) from July 35 
2013-August 2014, we estimated ESBL-E carriage prevalence on admission using rectal swab 36 
cultures and identified risk factors using logistic regression. Using twice-weekly follow up swabs, 37 
we estimated the incidence and identified risk factors for ESBL-E acquisition in hospital using 38 
Poisson regression.  39 
Results 40 
The prevalence of ESBL-E carriage at admission was 10% (59/569). Caesarean section delivery, 41 
older neonatal age, and smaller household size were significant risk factors. Of the 510 infants 42 
admitted without ESBL-E carriage, 238 (55%) acquired carriage during their hospital stay. The 43 
incidence of acquisition was 21.4% (95% CI 19.0, 24.0) per day. The rate was positively 44 
associated with the number of known neonatal ESBL-E carriers and with the total number of 45 
neonates on the same ward. 46 
Conclusions 47 
Carriage of ESBL-E was common among neonates on admission and acquisition in hospital was 48 
rapid. The dissemination and selection of ESBL-E appears to be driven by hospital exposures; 49 
operative delivery and neonatal ward patient density. Further attention to infection control, patient 50 
crowding and carriage surveillance is warranted. 51 
 52 
 3 
  53 
 4 
INTRODUCTION 54 
 55 
Infection and carriage rates of extended-spectrum beta-lactamase producing Enterobacterales 56 
(ESBL-E) are on the rise globally and pose a particular threat to neonates [1–3]. Outbreaks of 57 
multi-drug resistant infections due to ESBL-E in hospitals are common[4–7] and are a growing 58 
burden, especially among neonates[3].  59 
 60 
It is known that neonatal ESBL-E carriage can be a precursor to invasive infections[7,8] but the 61 
epidemiology of transmission in sub Saharan Africa (sSA) is poorly characterized. In sSA, data 62 
on neonatal ESBL-E infection and carriage are scarce[2,3] but there is some evidence of hospital-63 
acquired carriage in older children. In a general pediatric ward in Madagascar, prevalence of 64 
carriage of ESBL-E in stool was found to be 21% on admission and 57% on discharge, among 65 
patients discharged ≥48 hours after admission[9]. In the community, amongst children and adults 66 
in Madagascar[10], prevalence of ESBL carriage was 10%. 67 
 68 
At Kilifi County Hospital (KCH), we have observed sporadic outbreaks of ESBL-E bacteraemia 69 
among neonatal admissions over several years. These infections often have a poor outcome (in 70 
KCH the case-fatality risk for hospital-acquired paediatric bloodstream infections is  54%[11]). We 71 
have also observed an increase in the proportion of ESBL-producing invasive Klebsiella 72 
pneumoniae over a decade at Kilifi County hospital[12]. 73 
 74 
Here we report a prospective hospital-based longitudinal study at KCH to estimate the ESBL-E 75 
carriage prevalence among neonates on admission, the incidence of acquisition of ESBL-E 76 
carriage in hospital and the risk factors for neonatal prevalent and incident ESBL-E carriage. 77 
 78 
  79 
 5 
METHODS 80 
 81 
Study design and sampling procedure 82 
Neonatal admissions were eligible for recruitment into the study if they were admitted to the High 83 
Dependency Unit (HDU) between 1st July 2013 and 29th August 2014 or to the neonatal rooms in 84 
the general pediatric ward between 16th August 2013 and 29th August 2014. The HDU consists of 85 
an open ward with six beds for older children and two small rooms for neonatal admissions. The 86 
neonatal rooms are of equal size and have a combined bed-capacity of eight. In the general 87 
pediatric ward, there are two neonatal rooms with a combined bed-capacity of 24, including five 88 
incubators, four small beds and fifteen cots. KCH practices comprehensive obstetric care, as 89 
defined by the World Health Organization, with caesarean section services available.  90 
 91 
Data and clinical sample collection 92 
Epidemiological and clinical data were collected on admission and entered in real-time into an 93 
electronic medical record system. Rectal swabs were collected on admission (day 0), at days 2, 94 
4 and 6, and twice weekly thereafter until an ESBL-E was isolated or until hospital discharge or 95 
death, whichever came first. Rectal swabs were collected using pre-moistened viscose-tipped 96 
swabs and placed in Amies transport media (Deltalabs, Barcelona, Spain). The number of 97 
neonates in each room, bed-location and antimicrobial use of all participants was recorded daily. 98 
Blood culture is performed routinely at admission on all children hospitalized at KCH[13]. Clinical 99 
samples are collected at the discretion of the attending clinician. 100 
 101 
Laboratory procedure  102 
Rectal swabs were inoculated onto 5% horse blood agar and MacConkey agar supplemented 103 
with 8% gentamicin. Cefotaxime (30 ug) and ceftazidime (30 ug) antibiotic discs (Oxoid, United 104 
Kingdom) were added on the 2nd and 4th streaking zones on the blood agar plate to detect bacteria 105 
 6 
resistant to third-generation cephalosporins. Blood agar plates were incubated in a CO2 incubator 106 
while MacConkey agar plates were incubated in an aerobic incubator for 24 hours at 35 +/- 2OC. 107 
Oxidase-negative, gram-negative rods were subcultured and identified using standard techniques 108 
(API 20E; BioMérieux, France). Antimicrobial susceptibility testing was performed using the disc 109 
diffusion method according to the Clinical Laboratory Standards Institute (CLSI, 2014) 110 
guidelines[14]. ESBL testing was performed for isolates that were non-susceptible to third 111 
generation cephalosporins using the double disc method[14]. External quality assurance was 112 
provided for by UK National External Quality Assessment service. 113 
 114 
Analysis 115 
The binomial confidence interval around a prevalence estimate is widest (for a fixed sample size) 116 
when the estimate is 50%. We calculated that a sample size of 555 neonates would be required 117 
to estimate a 50% prevalence of ESBL-E carriage with a precision of +/-5%. 118 
 119 
Carriage on admission (prevalent carriage) was defined as a positive culture on the first rectal 120 
swab, provided it was obtained within 48 hours of admission. Logistic regression was used to 121 
determine risk factors for carriage at admission. The factors considered were: infant age, sex, 122 
maternal age, infant weight at admission, current method of feeding, place and mode of delivery, 123 
prematurity (less than or equal to 37 weeks gestation, estimated by the admitting clinician), 124 
number living in the same household, type of toilet and main source of water. Multivariable logistic 125 
regression models were fitted after confounders had been identified (Figure 1). Infant age at 126 
admission was adjusted for prematurity and place/mode of delivery, and prematurity was adjusted 127 
for age on admission. 128 
 129 
Kaplan-Meier curves were used to describe the time to acquisition of carriage in hospital among 130 
neonates who did not have ESBL-E carriage at admission. In this analysis, follow up time, which 131 
 7 
was measured in days after admission, was censored at the earliest of: (i) time of the first ESBL-132 
E culture positive swab (ii) time of last swab collection if the neonate died or was discharged and 133 
had remained negative throughout the course of admission. For neonates who acquired ESBL-E, 134 
the date of acquisition was assumed to be the midpoint between the date of the last negative 135 
swab and the date of the first positive swab.  136 
 137 
We calculated the rate of ESBL-E acquisition per 100 days at risk. Poisson regression was used 138 
to identify predictors of the acquisition rate and to test for interactions. The potential predictors 139 
were both time-invariant (e.g. weight at admission, place/mode of delivery, mother’s age and age 140 
at admission) and time-varying (e.g. number of known ESBL carriers on the ward). A multivariable 141 
Poisson regression model was fitted to investigate the effect of crowding on ESBL-E acquisition. 142 
The model included as covariates the ward, the number of neonates on the ward and the number 143 
of known ESBL-E carriers on the ward.  144 
 145 
We defined multi-drug resistance as resistance to at least one agent in three or more antimicrobial 146 
categories[15]. Statistical analyses were done with STATA 12.0 (StataCorp, College Station, TX, 147 
USA).  148 
 149 
Study clearance and ethical considerations 150 
The KEMRI National Ethical Review Committee approved the study (SSC 2301). Informed 151 
consent was obtained from all parents/guardians before enrollment. 152 
 153 
RESULTS 154 
During the study period, 1,014 neonates were admitted to Kilifi County Hospital, and the 155 
parents/guardians of 597 neonates gave consent for them to participate in the study (Figure 2). 156 
 8 
The median age of the participants was one day (IQR 0-3 days) and the median duration of 157 
hospital stay was 5 days (IQR 3-9 days). 158 
 159 
Of 597 who gave consent to participate, five parents/guardians withdrew consent and 23 160 
neonates had no swab collected. The prevalence of ESBL carriage at admission was 10% 161 
(59/569). From the 59 neonates with ESBL-E carriage at admission, there were 65 isolates 162 
consisting of 31 Klebsiella pneumoniae, 25 Escherichia coli, 8 Enterobacter cloacae and 1 163 
Klebsiella oxytoca. Multiple colonization, ie. colonization with two or more ESBL-E from one 164 
participant, was found in 6/59 neonates (10%). 165 
 166 
Among the 510 non-carriers on admission, 55% (283/510) acquired ESBL-E during their hospital 167 
stay. The incidence of ESBL-E acquisition was 21.4 (95% CI 19.0, 24.0) per 100 child days of 168 
observation, and the median time to acquisition among these patients was 3 (IQR 1-5) inpatient 169 
days (Figure 3). Nine neonates were diagnosed with ESBL-E bacteraemia during this study, all 170 
of whom had ESBL-E isolated from fecal carriage prior to or on the same day as blood was 171 
collected. 172 
 173 
Most ESBL-E isolates were multi-drug resistant; resistance to chloramphenicol, trimethoprim-174 
sulfamethoxazole, quinolones and gentamicin being common, none were resistant to imipenem 175 
and only 5% were resistant to amikacin (Table 1).  176 
 177 
Risk factors for ESBL-E carriage at admission 178 
In the univariable analysis, variables associated with prevalent ESBL-E carriage on admission 179 
were: being born at term, older infant age at admission, having fewer than eight people living in 180 
the same house, and hospital delivery, particularly by caesarean section (CS) (Table 2 and 181 
Supplementary Table S1). Babies born prematurely were more commonly admitted directly to the 182 
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neonatal ward (107/157, 68%) than babies born at full term (114/410, 28%; P-value<0.001). After 183 
adjusting for prematurity and place/mode of delivery, increasing infant age was positively 184 
associated (p<0.001) with ESBL-E carriage at admission, with odds ratios 1.72 (95% CI 0.69 – 185 
4.27) and 3.88 (95% CI 1.47 - 10.21) among neonates aged 1-2 days and 3-28 days respectively, 186 
relative to the odds of ESBL carriage among neonates admitted on the day of birth. Being born at 187 
term was not associated with ESBL-E carriage after adjusting for the effect mediated through age 188 
on admission. We did not estimate an adjusted OR for place/mode of delivery and number of 189 
people in the same household since the associations were not confounded (Figure 1). 190 
 191 
Risk factors associated with acquisition of ESBL-E during hospitalization 192 
In the univariable analysis, hospital ward on admission, the number of neonates present in the 193 
hospital, the number of other neonates admitted in the same ward, and the number of known 194 
ESBL-E carriers were associated with incident acquisition of carriage (Table 3). Both current 195 
number of known neonatal ESBL-E carriers and number of other neonates in the same ward were 196 
positively associated with carriage acquisition when simultaneously included in multivariable 197 
model (Table 4), and there was no interaction between these risk factors. In both the univariable 198 
and multivariable analyses, the number of neonates in the ward exhibited a threshold effect 199 
whereby there was a plateau effect in carriage acquisition beyond 10 patients per ward. Recorded 200 
antibiotic prescription, specifically use of third generation cephalosporins during the inpatient stay 201 
was not shown to be associated with ESBL-E acquisition.  202 
 203 
DISCUSSION 204 
Our study reveals that among neonates admitted to a rural Kenyan hospital, 10% were already 205 
carriers of ESBL-E. Among those neonates who were not carriers at admission, 21.4% acquired 206 
ESBL-E carriage each day of admission; thus, more than half of the neonates were colonized with 207 
ESBL within the first three inpatient days.  208 
 10 
 209 
For babies coming in to hospital, the main risk factors for existing rectal carriage with ESBL-E 210 
were delivery in hospital via caesarean section and older infant age at admission. For those 211 
admitted without carriage of ESBL-E, the principal risk factors for acquisition in hospital were the 212 
number of other neonates in the ward and the number with ESBL-E carriage.  213 
Delivery through caesarean section has been reported to be a significant risk factor for prolonged 214 
faecal colonization with ESBL producing K. pneumoniae[16] and also a determinant of intestinal 215 
microflora early in life[17,18]. Mothers undergoing caesarean section are treated with antibiotics 216 
for surgical prophylaxis, sometimes extended to treatment of wound infections[19], which may 217 
select for antibiotic-resistant enteric bacteria. In Cambodia, young hospital-born infants were 218 
found to be at a greater risk of early colonization by third generation cephalosporin resistant gram-219 
negative rods compared to infants born at home, a health centre or other locations and 220 
subsequently admitted to hospital[20].  In Madagascar, Herindrainy et al. reported that low birth 221 
weight, caesarean section and use of antibiotics by mothers at delivery were independently 222 
associated with neonatal acquisition of ESBL-E during the first month of life[21].  223 
The finding that babies coming from a large family of >8 household members were less likely to 224 
carry ESBL-E at admission was surprising. We speculate that these neonates may have a more 225 
diverse gut microbiome, which could be protective against acquisition of ESBL-E carriage. 226 
Increased neonatal age at hospital admission was associated with a greater likelihood of ESBL-227 
E carriage, as expected, since older neonates have had more time to acquire carriage.  228 
Overall, we isolated ESBL-E from 10% of swabs within 48 hours of admission. In a cross-sectional 229 
ESBL-E carriage study done in a Tanzanian hospital, the overall neonatal prevalence of ESBL-E 230 
carriage was 25.4% [22]. Our findings suggest that some acquisition occurs before neonates 231 
come into the paediatric wards and we can speculate that this does not only come from their 232 
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mothers but also from the procedures and settings of childbirth, particularly caesarian delivery. 233 
We did not collect data on ESBL-E carriage in mothers or maternal antibiotic use. 234 
 235 
Among neonates admitted without carriage, 55% acquired ESBL-E during hospitalization. An 236 
ESBL-E carriage study in a tertiary hospital in Rwanda among inpatients of all ages reported that 237 
55% of participants acquired ESBL-E carriage during hospitalization [23]. A study in Madagascar 238 
reported that 48% of pediatric non-carriers at admission acquired ESBL-E during hospitalization. 239 
 240 
Our findings from the longitudinal study suggest that the greatest risk factors for ESBL-E 241 
acquisition in hospital were having increased numbers of existing ESBL-E carriers among the 242 
neonatal patients and a greater number of neonates admitted to the ward. We assume that 243 
increased numbers of ESBL-E carriers increase the opportunity for transmission. This finding 244 
corresponds with a prospective cohort study done in the general intensive care unit of a hospital 245 
in Greece; colonization pressure contributed significantly to acquisition of carriage of 246 
carbapenemase producing Klebsiella pneumoniae in hospital[24]. Intuitively, hospital crowding is 247 
expected to be associated with higher rates of ESBL-E transmission and our results support this. 248 
However, our findings suggest a threshold effect where risk plateaued after admitting more than 249 
10-14 neonates in a ward, suggesting that transmission effects associated with crowding are 250 
complex. Restricting the number of neonatal admissions to the hospital is impractical, but this 251 
does justify allocating increased space to neonatal admissions. Fixed low healthcare staff 252 
numbers relative to numbers of patients, the cultural practice of mothers caring for each other’s 253 
babies on the ward, physical proximity of adjacent neonates, and shared hygiene facilities, may 254 
all contribute to acquisition of ESBL-E carriage by neonates in hospital. As well as direct 255 
transmission between babies on the ward, nosocomial carriage acquisition directly from the 256 
hospital environment is also possible. A study in Cambodia of transmission of third-generation 257 
cephalosporin-resistant Klebsiella pneumoniae isolates in a newly opened neonatal unit found 258 
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that most clusters were likely to have been due to patient sources while 2 of 9 clusters could have 259 
been due to either an environmental or a patient source[25]. 260 
 261 
During the study period, nine neonates were diagnosed with ESBL-E bacteraemia. Nosocomial 262 
spread of ESBL-E carriage may result in outbreaks of ESBL-E bacteraemia in the hospital; such 263 
outbreaks have occurred in KCH in recent years [12], signifying the importance of awareness of 264 
ESBL-E carriage. There is potential for surveillance to help inform hospital infection control and 265 
to assist in averting such outbreaks. At KCH screening for carriage of ESBL-E among neonates 266 
is not routinely done, hand washing facilities frequently lack water supply, and there are no fully 267 
dedicated infection control staff. 268 
 269 
Antibiotic use has been shown to affect the composition of gut microbiota and is associated with 270 
ESBL-E carriage and acquisition[9,16,17,24,26]. Antimicrobial stewardship services are used as 271 
part of hospital infection control services to reduce ESBL carriage in well-resourced hospitals. We 272 
were unable to detect antibiotic use as a risk factor for ESBL-E acquisition in our study. We 273 
suspect that this is mainly attributed to the fact that 93% of our participants were given antibiotics 274 
during their hospital stay and we were therefore underpowered to observe any differences 275 
(Supplementary table S2).  276 
 277 
We did not collect data from babies after they were discharged from hospital, but patients 278 
discharged with ESBL-E carriage have been shown to spread these ESBL-E within family units 279 
and close contacts[16,27]. In a prospective cohort study of infants and their families in Norway, 280 
the median carriage duration among infants discharged with carriage of ESBL-producing 281 
Klebsiella pneumoniae after a hospital outbreak was 12.5 months[16]. If carriage of ESBL-E 282 
persists and intra-household transmission occurs, discharged patients may act as reservoirs of 283 
ESBL-E in the community. 284 
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 285 
Being a hospital-based study, focusing on sick newborns, our estimates of ESBL-E prevalence at 286 
admission cannot be generalized to community prevalence. It is theoretically possible that low-287 
level ESBL-E carriage was more prevalent at admission than we were able to determine; below 288 
detection rate by culture methods, but then amplified by selection pressure from the use of 289 
antibiotics in hospital until detectable. We also were only able to recruit 68% of eligible neonates 290 
limiting the generalizability of our findings (Supplementary table S1). Of note, significantly more 291 
parents/guardians of older neonates, and neonates born in hospital by caesarean section, 292 
declined to participate in the study suggesting that our estimate of prevalence of ESBL-E carriage 293 
at admission is likely to be an underestimate. Our prevalence and incidence estimates may also 294 
be underestimates since stool culture may be more sensitive than rectal swab culture, a single 295 
sample is less sensitive than multiple samples for culture and some Enterobacter spp, which are 296 
known to produce AmpC beta-lactamases, may have tested falsely-negative for ESBL by the 297 
phenotypic method used.  We did not find any carbapenem resistant Enterobacterales (CRE) in 298 
this study, but it is known that such isolates are present in Kenya[28,29]. Use of central quality 299 
assured microbiology laboratories in surveillance for ESBL-E carriage could therefore be 300 
expected to have the added benefit of an early warning system for the introduction of CRE 301 
carriage. 302 
 303 
In conclusion, our findings reveal a high incidence of ESBL-E colonization among hospitalized 304 
neonates, which is endemic in this setting. Further work to investigate the association between 305 
ESBL-E acquisition and both caesarean section delivery and crowding, perhaps including 306 
restrictions on room capacity, and more deliberate cohorting of older neonates and those born in 307 
hospital through caesarean section is needed. Given the link between ESBL-E carriage and 308 
outbreaks of potentially fatal ESBL-E infection, our data emphasize the importance of routine 309 
surveillance and hospital infection control. 310 
311 
 14 
Funding  312 
This work was supported by the Medical Research Council/Department for International 313 
Development/Wellcome Trust- Joint Global Health Trials scheme [MR/M007367/1 to J.A.B] and 314 
the Wellcome Trust [098532 to J.A.G.S; 093804 and 205184 to ACS]. 315 
 316 
Acknowledgements 317 
This study is published with the permission of the director Kenya Medical Research Institute, 318 
Nairobi. We would like to thank Irene Mutuku and John Ojal for their help in setting up the study. 319 
The authors also thank all participants, the Kilifi County hospital management, clinical team and 320 
the laboratory staff for their involvement in this work.  321 
322 
 15 
REFERENCES 323 
1.  Folgori L, Bielicki J, Heath PT, Sharland M. Antimicrobial-resistant Gram-negative 324 
infections in neonates: burden of disease and challenges in treatment. Curr. Opin. Infect. 325 
Dis. 2017; 30:281–288.  326 
2.  Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of 327 
Extended-Spectrum Beta-lactamases in the community: Toward the globalization of CTX-328 
M. Clin. Microbiol. Rev. 2013; 26:744–758.  329 
3.  Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum β-lactamase-producing 330 
Enterobacteriaceae in children: Old Foe, Emerging Threat. Clin. Infect. Dis. 2015; 331 
60:1389–1397.  332 
4.  Belbel Z, Chettibi H, Dekhil M, Ladjama A, Nedjai S, Rolain J-M. Outbreak of an armA 333 
methyltransferase-producing ST39 Klebsiella pneumoniae clone in a pediatric Algerian 334 
Hospital. Microb. Drug Resist. 2014; 20:310–5.  335 
5.  Gaibani P, Colombo R, Arghittu M, et al. Successful containment and infection control of 336 
a Carbapenem-resistant Klebsiella pneumoniae outbreak in an Italian hospital. New 337 
Microbiol. 2014; 37:87–90.  338 
6.  Carrër A, Lassel L, Fortineau N, et al. Outbreak of CTX-M-15-producing Klebsiella 339 
pneumoniae in the intensive care unit of a French hospital. Microb. Drug Resist. 2009; 340 
15:47–54.  341 
7.  Lucet JC, Chevret S, Decré D, et al. Outbreak of multiply resistant Enterobacteriaceae in 342 
an intensive care unit: epidemiology and risk factors for acquisition. Clin. Infect. Dis. 343 
 16 
1996; 22:430–436.  344 
8.  Litzow JM, Gill CJ, Mantaring JB V, et al. High frequency of multidrug-resistant gram-345 
negative rods in 2 neonatal intensive care units in the Philippines. Infect. Control Hosp. 346 
Epidemiol. 2009; 30:543–549.  347 
9.  Andriatahina T, Randrianirina F, Hariniana ER, et al. High prevalence of fecal carriage of 348 
extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae 349 
in a pediatric unit in Madagascar. BMC Infect. Dis. 2010; 10:204.  350 
10.  Herindrainy P, Randrianirina F, Ratovoson R, et al. Rectal carriage of extended-spectrum 351 
beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. 352 
PLoS One 2011; 6:e22738.  353 
11.  Aiken AM, Mturi N, Njuguna P, et al. Risk and causes of paediatric hospital-acquired 354 
bacteraemia in Kilifi District Hospital, Kenya: A prospective cohort study. Lancet. 2011; 355 
378:2021–2027.  356 
12.  Henson SP, Boinett CJ, Ellington MJ, et al. Molecular epidemiology of Klebsiella 357 
pneumoniae invasive infections over a decade at Kilifi County Hospital in Kenya. Int. J. 358 
Med. Microbiol. 2017; 307:422–429.  359 
13.  Seale AC, Davies MR, Anampiu K, et al. Invasive Group A Streptococcus Infection 360 
among Children, Rural Kenya. Emerg. Infect. Dis. 2016; 22:224–32.  361 
14.  Wayne P. A. CLSI: Perfomance standards for antimicrobial susceptibility testing; twenty-362 
fourth informational supplement. Clinical and Laboratory Standards Institute, 2014.  363 
 17 
15.  Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-364 
resistant and pandrug-resistant bacteria: an international expert proposal for interim 365 
standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18:268–81.  366 
16.  Löhr IH, Rettedal S, Natås OB, Naseer U, Øymar K, Sundsfjord A. Long-term faecal 367 
carriage in infants and intra-household transmission of CTX-M-15-producing Klebsiella 368 
pneumoniae following a nosocomial outbreak. J. Antimicrob. Chemother. 2013; 68:1043–369 
1048.  370 
17.  Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal 371 
microbiota in early infancy. Pediatrics 2006; 118:511–521.  372 
18.  Gritz EC, Bhandari V. The human neonatal gut microbiome: a brief review. Front. Pediatr. 373 
2015; 3:17.  374 
19.  Aiken AM, Wanyoro AK, Mwangi J, et al. Evaluation of surveillance for surgical site 375 
infections in Thika Hospital , Kenya. J. Hosp. Infect. 2013; 83:140–145.  376 
20.  Turner P, Pol S, Soeng S, et al. High Prevalence of Antimicrobial-resistant Gram-negative 377 
Colonization in Hospitalized Cambodian Infants. Pediatr. Infect. Dis. J. 2016; 35:856–61.  378 
21.  Herindrainy P, Rabenandrasana MAN, Andrianirina ZZ, et al. Acquisition of extended 379 
spectrum beta-lactamase-producing Enterobacteriaceae in neonates: A community based 380 
cohort in Madagascar. PLoS One 2018; 13:e0193325.  381 
22.  Nelson E, Kayega J, Seni J, et al. Evaluation of existence and transmission of extended 382 
spectrum beta lactamase producing bacteria from post-delivery women to neonates at 383 
 18 
Bugando Medical Center, Mwanza-Tanzania. BMC Res. Notes 2014; 7:279.  384 
23.  Kurz MSE, Bayingana C, Ndoli JM, et al. Intense pre-admission carriage and further 385 
acquisition of ESBL-producing Enterobacteriaceae among patients and their caregivers in 386 
a tertiary hospital in Rwanda. Trop. Med. Int. Health 2017; 22:210–220.  387 
24.  Papadimitriou-Olivgeris M, Christofidou M, Fligou F, et al. The role of colonization 388 
pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella 389 
pneumoniae in critically ill patients. Infection 2014; 42:883–90.  390 
25.  Smit PW, Stoesser N, Pol S, et al. Transmission Dynamics of Hyper-Endemic Multi-Drug 391 
Resistant Klebsiella pneumoniae in a Southeast Asian Neonatal Unit: A Longitudinal 392 
Study With Whole Genome Sequencing. Front. Microbiol. 2018; 9.  393 
26.  Nordberg V, Quizhpe Peralta A, Galindo T, et al. High proportion of intestinal 394 
colonization with successful epidemic clones of ESBL-producing Enterobacteriaceae in a 395 
neonatal intensive care unit in Ecuador. PLoS One 2013; 8:e76597.  396 
27.  Magoué CL, Melin P, Gangoué-Piéboji J, Okomo Assoumou M-C, Boreux R, De Mol P. 397 
Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae 398 
in Ngaoundere, Cameroon. Clin. Microbiol. Infect. 2013; 19:E416-20.  399 
28.  Maina D, Omuse G, Revathi G, Adam RD. Spectrum of microbial diseases and resistance 400 
patterns at a private teaching hospital in Kenya: Implications for clinical practice. PLoS 401 
One 2016; 11:1–12.  402 
29.  Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing Klebsiella 403 
 19 
pneumoniae in Kenya. Antimicrob. Agents Chemother. 2011; 55:934–6.  404 
 405 
  
Table 1: Non-susceptibility profile for Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae carriage isolates 
 
Antibiotic tested  Timing of admission Klebsiella pneumoniae Escherichia coli Enterobacter cloacae 
on admission N=31 N=25 N=8 
after admission N=196 N=73 N=42 
  n  % n  % n  % 
Chloramphenicol on admission 11 35.5 3 12.0 7 87.5 
 after admission 66 33.7 17 23.3 33 78.6 
        
Ciprofloxacin on admission 13 41.9 16 64.0 5 62.5 
 after admission 99 50.5 64 87.7 25 59.5 
        
Cotrimoxazole on admission 31 100 22 88.0 7 87.5 
 after admission 193 98.5 70 95.9 38 90.5 
        
Gentamicin on admission 30 96.8 11 44.0 7 87.5 
 after admission 192 98.0 58 79.5 38 90.5 
        
Amikacin on admission 2 6.5 1 4.0 0 0 
 after admission 19 9.7 3 4.1 2 4.8 
        
Imipenem on admission 0 0 0 0 0 0 
 after admission 0 0 0 0 0 0 
 
 On admission:        48 hours after admission   
 
After admission:      >48 hours after admission 
 
All isolates were Extended Spectrum beta-lactamase producing Enterobacterales
Table Click here to access/download;Table;Neonatal carriage and acquisition of ESBL-E
T&Fv2.docx
  
Table 2. Univariable analysis of risk factors for Extended Spectrum Beta-
lactamase producing Enterobacterales colonization at admission 
 
Variable n N % OR 95% CI P-value 
Prematurity      0.017 
No 50 410 12.2 1   
Yes 9 157 5.7 0.44 0.21 - 0.91  
Weight at admission      0.083 
<2.5Kgs 20 250 8.0 1   
≥2.5Kgs 39 313 12.5 1.64 0.93 - 2.89  
Sex      0.327 
Males 31 333 9.3 1   
Females 28 236 11.9 1.31 0.76 - 2.25  
Age at admission      <0.001 
0 days 8 221 3.6 1   
1-2 days 16 177 9.0 2.65 1.11 - 6.33  
3-28 days 35 171 20.5 6.85 3.09 - 15.21  
Place/mode of delivery      0.002 
Community 6 116 5.2 1   
Hospital non-CS 32 339 9.4 1.91 0.78 - 4.69  
Hospital CS 21 105 20.0 4.58 1.77 - 11.86  
Mother’s age      0.780 
<18 years 6 54 11.1 1   
18-35 years 47 455 10.3 0.92 0.37 - 2.27  
>35 years 4 53 7.6 0.65 0.17 - 2.46  
Main water source      0.153 
Tap in the compound 27 179 15.1 1   
Tap in community 24 245 9.8 0.61 0.34 - 1.10  
Borehole in community 6 54 11.1 0.70 0.27 - 1.81  
Natural source 1 33 3.0 0.18 0.02 - 1.34  
Water vendor 1 18 5.6 0.33 0.04 - 2.59  
Current feed      0.251 
Breastfeeding 39 315 12.4 1   
No breastfeeding 17 187 9.1 0.71 0.39 - 1.29  
Type of toilet      0.169 
Toilet in house 16 122 13.1 1   
Toilet shared in 
compound/community 37 333 11.1 0.83 0.44 - 1.55  
None 6 101 5.9 0.42 0.16 - 1.11  
Number of people living in the same house   0.012 
1-4 29 227 12.8 1   
5-7 22 167 13.2 1.04 0.57 - 1.88  
8-40 8 162 4.9 0.35 0.16 - 0.80   
 
CS Caesarean section;  
CI Confidence interval 
  
at admission:          swabs collected within 48 hours after admission 
 
Missing data: Prematurity n=2, Weight at admission n=6, Place/mode of delivery n=9, Mother’s age n=7, 
Main water source n=40, Current feed n=67, Type of toilet n=13, Number of people living in the same house 
n=13 
CS Caesarean section  
CI Confidence interval 
  
  
Table 3. Univariable analysis of risk factors for acquisition of Extended Spectrum 
Beta-lactamase producing Enterobacterales (ESBL-E) colonization in hospital 
 
Variable  Events 
Person 
days Rate§  
Rate 
ratio 95% CI  P-value 
Prematurity        0.948 
No 171 802.5 21.31 1   
Yes 112 521.5 21.48 1.01 0.79 - 1.28  
Weight at admission      0.979 
<2.5kgs 153 709 21.58 1   
≥2.5kgs 126 582 21.65 1.00 0.79 - 1.27  
Sex      0.155 
Males 168 731 22.98 1   
Females 115 594 19.36 0.84 0.66 - 1.07  
Age at admission       0.769 
0 days 127 622 20.42 1   
1-2 days 82 364 22.53 1.10 0.84 - 1.46  
3-28 days 74 339 21.83 1.07 0.80 - 1.42  
Place/mode of delivery    0.185 
Community  74 354 20.90 1   
Hospital, non-CS 160 769 20.81 1.00 0.76 - 1.31  
Hospital, CS  47 166.5 28.23 1.35 0.94 - 1.95  
Mother’s age      0.583 
 <18 years 27 146.5 18.43 1   
18-35 years  228 1060 21.51 1.17 0.78 - 1.74  
>35 years  25 102 24.51 1.33 0.77 - 2.29  
Treated with antibiotics    0.566 
No 20 82.5 24.24 1   
Yes 263 1242.5 21.17 0.87 0.55 - 1.38  
Treated with ampicillin and gentamicin    0.403 
No 35 143 24.48 1   
Yes 248 1182 20.98 0.86 0.60 - 1.22  
Treated with third-generation cephalosporins     0.44 
No 206 937 21.99 1   
Yes 77 388 19.85 0.90 0.69 - 1.17  
Duration of antibiotic use    0.627 
1-3 days 24 133.5 17.98 1   
4-7 days 135 624 21.63 1.20 0.78 - 1.86  
>7 days 104 468 22.22 1.24 0.79 - 1.93  
  
Variable  Events 
Person 
days Rate§  
Rate 
ratio 95% CI  P-value 
Number of neonates present in the hospital per day 0.001 
1-19 71 465.5 15.25 1   
20-32 163 662 24.62 1.61 1.22 - 2.13  
33-45 49 197.5 24.81 1.63 1.13 - 2.34  
Number of known ESBL-E carriers per day    <0.001 
0-4 22 260.5 8.45 1   
5-9 88 477 18.45 2.18 1.37 - 3.49  
10-14 122 407 29.98 3.55 2.25 - 5.59  
15-21 51 180.5 28.25 3.35 2.03 - 5.52  
Number of neonates on the same ward    <0.001 
0-4 14 146 9.59 1   
5-9 49 357 13.73 1.43 0.79 - 2.59  
10-14 70 282.5 24.78 2.58 1.46 – 4.59  
15-20 81 290 27.93 2.91 1.65 – 5.14  
21-29 69 249.5 27.66 2.88 1.62 – 5.12  
Ward at admission      0.003 
HDU 45 302 14.90 1   
General pediatric 236 1004 23.51 1.58 1.15 - 2.17  
Current feed      0.599 
Breastfeeding 140 661.5 21.16 1   
No breastfeeding 111 490.5 22.63 1.07 0.83 - 1.37  
Type of toilet      0.943 
Toilet in house 57 248 22.98 1   
Toilet shared with 
community 
162 733 22.10 0.96 0.71 - 1.30  
None 59 255.5 23.09 1.00 0.70 - 1.45  
Main water source      0.327 
Tap in compound 87 328.5 26.48 1   
Tap in community  124 554 22.38 0.85 0.64 - 1.11  
Borehole in 
community  
26 141 18.44 0.70 0.45 - 1.08  
Natural source 19 84.5 22.49 0.85 0.52 - 1.39  
Water vendor 7 47 14.89 0.56 0.26 - 1.21  
Number of people living in the same house    0.227 
1-4 112 440 25.45 1   
5-7 85 425.5 19.98 0.78 0.59 - 1.04  
8-40 81 371 21.83 0.86 0.64 - 1.14   
 
  
CS Caesarean section; HDU High dependency unit;  
§ Rate per 100 person day 
  
  
Table 4: Multivariable analysis of risk factors for acquisition of Extended 
Spectrum Beta-lactamase producing Enterobacterales (ESBL-E) colonization in 
hospital 
 
    Rate ratio 95% CI  P-value 
Number of known ESBL-E carriers §   
0-4  1  <0.001 
5-9  1.77 1.09 - 2.88  
10-14  2.80 1.70 - 4.59  
15-21  2.57 1.48 – 4.48  
Number of neonates on the same ward §§ 
 0.025 
0-4  1   
5-9  1.35 0.74 - 2.46  
10-14  2.13 1.16 - 3.90  
15-20  1.90 1.04 - 3.48  
21-29   1.76 0.93 - 3.31   
 
§ Rate ratio adjusted for number of neonates on the same ward and ward at admission. 
§§ Rate ratio adjusted for number of known ESBL-E carriers and ward at admission. 
 
  
FIGURE LEGENDS 
 
Figure 1: Causal diagram for determinants of Extended Spectrum Beta-lactamase 
producing Enterobacterales carriage at admission  
Footnote: 
Only variables that had plausible interactions as shown in the casual diagram were included in the multivariable model 
 
Figure 2: Flow of subjects recruited in the study 
Footnote: Figure 2. 
Among the n=177 not eligible neonatal admissions: 57 were admitted to the general pediatric ward before the study rolled 
out in that ward, 42 died before consenting, 30 not consented because there was no competent adult available to provide 
consent on behalf of the child within the first 48 hours of admission, 21 were discharged on admission, 5 were cases of 
readmission and their ESBL-E carriage status was known, 5 were not followed up after admission, 4 absconded and could 
not be traced after admission, 4 were considered too tiny for a sample to be collected, 3 were admitted for elective surgery 
and consenting was not done, 2 had congenital abnormalities and were not approached to participate, 2 could not be 
enrolled because the parent was a minor, 1 was not consented because the mother could not be approached for consenting, 
and 1 was enrolled after  recruitment had stopped. +ve; positive and –ve; negative. 
 
 
Figure 3: Kaplan-Meier estimate of Extended Spectrum Beta-lactamase producing 
Enterobacterales (ESBL-E) carriage acquisition as a function of days after 
admission among 510 neonates who were ESBL-E carriage negative at admission 
 
Figure 1 (.tif and .eps files only) Click here to access/download;Figure (.tif and .eps files
only);Figure_1_C_diagram.eps
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Table S1. Characteristics of study neonates and those who were eligible but not 
included, either because they were not swabbed, or because they withdrew prior 
to the start of the study, or because their parents did not provide consent. 
 
Characteristic 
Included in study  
(N=569) 
Excluded from study 
(N=268) 
P - value n % n % 
Sex     0.695 
Male 333 58.5 153 57.1  
Females 236 41.5 115 42.9  
Age at admission      0.454 
0 days 221 38.8 93 34.7  
1-2 days 177 31.1 93 34.7  
3-28days 171 30.1 82 30.6  
Weight at admission     0.026 
<2.5kgs 250 44.4 96 36.2  
≥2.5kgs 313 55.6 169 63.8  
Prematurity     0.004 
Yes 157 27.7 49 18.5  
No 410 72.3 216 81.5  
Place/mode of delivery     0.005 
Community  116 20.7 30 11.4  
Hospital, non-CS 339 60.5 175 66.5  
Hospital, CS  105 18.8 58 22.1  
Mother’s age     0.098 
 <18 years 54 9.6 14 5.2  
18-35 years  455 81.0 228 85.4  
>35 years  53 9.4 25 9.4   
 
CS Caesarean section 
 
Missing data:  
Included in the study; Weight n=6, Prematurity n=2, Place/mode delivery n=9, Mother’s age n=7 and 
Excluded from the study; Weight n=3, Prematurity n=3, Place/mode delivery n=5, Mother’s age n=1 
  
Table S2 Summaries on Antibiotics given for the 510 neonates recruited into 
the study 
      n % 
Antibiotics given   475 93.1 
Given ampicillin and gentamicin   455 89.2 
Treated with a third generation cephalosporin 116 22.8 
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ABSTRACT 27 
 28 
Background 29 
Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) 30 
among hospitalized neonates in sub-Saharan Africa pose significant clinical challenges. Data on 31 
prevalence and acquisition of ESBL-E carriage among hospitalized neonates in the region are 32 
few and However, sources of infection and risk factors for transmission are not clearly defined in 33 
this setting. 34 
Methods  35 
In a cohort study of consecutive neonatal admissions to Kilifi County Hospital (KCH) from July 36 
2013-August 2014, we estimated ESBL-E carriage prevalence on admission using rectal swab 37 
cultures and identified risk factors using logistic regression. Using twice-weekly follow up swabs, 38 
we estimated the incidence and identified risk factors for ESBL-E acquisition in hospital using 39 
Poisson regression.  40 
Results 41 
The prevalence of ESBL-E carriage at admission was 10% (59/569). Caesarean section delivery, 42 
older neonatal age, and smaller household size were significant risk factors. Of the 510 infants 43 
admitted without ESBL-E carriage, 238 (55%) acquired carriage during their hospital stay. The 44 
incidence of acquisition was 21.4% (95% CI 19.0, 24.0) per day. The rate was positively 45 
associated with the number of known neonatal ESBL-E carriers and with the total number of 46 
neonates on the same ward. 47 
Conclusions 48 
Carriage of ESBL-E was common among neonates on admission and acquisition in hospital was 49 
rapid. The dissemination and selection of ESBL-E appears to be driven by hospital exposures; 50 
operative delivery and neonatal ward patient density. Further attention to infection control, patient 51 
crowding and carriage surveillance is warranted. 52 
 3 
 53 
  54 
 4 
INTRODUCTION 55 
 56 
Infection and carriage rates of extended-spectrum beta-lactamase producing Enterobacterales 57 
(ESBL-E) are on the rise globally and pose a particular threat to neonates [1–3]. Outbreaks of 58 
multi-drug resistant infections due to ESBL-E in hospitals are common[4–7] and are a growing 59 
burden, especially among neonates[3].  60 
 61 
It is known that neonatal ESBL-E carriage can be a precursor to invasive infections[7,8] but the 62 
epidemiology of transmission in sub Saharan Africa (sSA) is poorly characterized. In sSA, data 63 
on neonatal ESBL-E infection and carriage are scarce[2,3] but there is some evidence of hospital-64 
acquired carriage in older children. In a general pediatric ward in Madagascar, prevalence of 65 
carriage of ESBL-E in stool was found to be 21% on admission and 57% on discharge, among 66 
patients discharged ≥48 hours after admission[9]. In the community, amongst children and adults 67 
in Madagascar[10], prevalence of ESBL carriage was 10%. 68 
 69 
At Kilifi County Hospital (KCH), we have observed sporadic outbreaks of ESBL-E bacteraemia 70 
among neonatal admissions over several years. These infections often have a poor outcome (in 71 
KCH the case-fatality risk for hospital-acquired paediatric bloodstream infections is  54%[11]). We 72 
have also observed an increase in the proportion of ESBL-producing invasive Klebsiella 73 
pneumoniae over a decade at Kilifi County hospital[12]. 74 
 75 
Here we report a prospective hospital-based longitudinal study at KCH to estimate the ESBL-E 76 
carriage prevalence among neonates on admission, the incidence of acquisition of ESBL-E 77 
carriage in hospital and the risk factors for neonatal prevalent and incident ESBL-E carriage. 78 
 79 
  80 
 5 
METHODS 81 
 82 
Study design and sampling procedure 83 
Neonatal admissions were eligible for recruitment into the study if they were admitted to the High 84 
Dependency Unit (HDU) between 1st July 2013 and 29th August 2014 or to the neonatal rooms in 85 
the general pediatric ward between 16th August 2013 and 29th August 2014. The HDU consists of 86 
an open ward with six beds for older children and two small rooms for neonatal admissions. The 87 
neonatal rooms are of equal size and have a combined bed-capacity of eight, although doubling 88 
up of neonates in beds or cots is frequently necessary at KCH. . In the general pediatric ward, 89 
there are two neonatal rooms with a combined bed-capacity of 24, including five incubators, four 90 
small beds and fifteen cots. KCH practices comprehensive obstetric care, as defined by the World 91 
Health Organization, with caesarean section services available.  92 
 93 
Data and clinical sample collection 94 
Epidemiological and clinical data were collected on admission and entered in real-time into an 95 
electronic medical record system. Rectal swabs were collected on admission (day 0), at days 2, 96 
4 and 6, and twice weekly thereafter until an ESBL-E was isolated or until hospital discharge or 97 
death, whichever came first. Rectal swabs were collected using pre-moistened viscose-tipped 98 
swabs and placed in Amies transport media (Deltalabs, Barcelona, Spain). The number of 99 
neonates in each room, bed-location and antimicrobial use of all participants was recorded daily. 100 
Blood culture is performed routinely at admission on all children hospitalized at KCH[13]. Clinical 101 
samples are collected at the discretion of the attending clinician. 102 
 103 
Laboratory procedure  104 
Rectal swabs were inoculated onto 5% horse blood agar and MacConkey agar supplemented 105 
with 8% gentamicin. Cefotaxime (30 ug) and ceftazidime (30 ug) antibiotic discs (Oxoid, United 106 
 6 
Kingdom) were added on the 2nd and 4th streaking zones on the blood agar plate to detect bacteria 107 
resistant to third-generation cephalosporins. Blood agar plates were incubated in a CO2 incubator 108 
while MacConkey agar plates were incubated in an aerobic incubator for 24 hours at 35 +/- 2OC. 109 
Oxidase-negative, gram-negative rods were subcultured and identified using standard techniques 110 
(API 20E; BioMérieux, France). Antimicrobial susceptibility testing was performed using the disc 111 
diffusion method according to the Clinical Laboratory Standards Institute (CLSI, 2014) 112 
guidelines[14]. ESBL testing was performed for isolates that were non-susceptible to third 113 
generation cephalosporins using the double disc method[14]. External quality assurance was 114 
provided for by UK National External Quality Assessment service. 115 
 116 
Analysis 117 
The binomial confidence interval around a prevalence estimate is widest (for a fixed sample size) 118 
when the estimate is 50%. We calculated that a sample size of 555 neonates would be required 119 
to estimate a 50% prevalence of ESBL-E carriage with a precision of +/-5%. 120 
 121 
Carriage on admission (prevalent carriage) was defined as a positive culture on the first rectal 122 
swab, provided it was obtained within 48 hours of admission. Logistic regression was used to 123 
determine risk factors for carriage at admission. The factors considered were: infant age, sex, 124 
maternal age, infant weight at admission, current method of feeding, place and mode of delivery, 125 
prematurity (less than or equal to 37 weeks gestation, estimated by the admitting clinician), 126 
number living in the same household, type of toilet and main source of water. Multivariable logistic 127 
regression models were fitted after confounders had been identified (Figure 1). Infant age at 128 
admission was adjusted for prematurity and place/mode of delivery, and prematurity was adjusted 129 
for age on admission. 130 
 131 
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Kaplan-Meier curves were used to describe the time to acquisition of carriage in hospital among 132 
neonates who did not have ESBL-E carriage at admission. In this analysis, follow up time, which 133 
was measured in days after admission, was censored at the earliest of: (i) time of the first ESBL-134 
E culture positive swab (ii) time of last swab collection if the neonate died or was discharged and 135 
had remained negative throughout the course of admission. For neonates who acquired ESBL-E, 136 
the date of acquisition was assumed to be the midpoint between the date of the last negative 137 
swab and the date of the first positive swab.  138 
 139 
We calculated the rate of ESBL-E acquisition per 100 days at risk. Poisson regression was used 140 
to identify predictors of the acquisition rate and to test for interactions. The potential predictors 141 
were both time-invariant (e.g. weight at admission, place/mode of delivery, mother’s age and age 142 
at admission) and time-varying (e.g. number of known ESBL carriers on the ward). A multivariable 143 
Poisson regression model was fitted to investigate the effect of crowding on ESBL-E acquisition. 144 
The model included as covariates the ward, the number of neonates on the ward and the number 145 
of known ESBL-E carriers on the ward.  146 
 147 
We defined multi-drug resistance as resistance to at least one agent in three or more antimicrobial 148 
categories[15]. Statistical analyses were done with STATA 12.0 (StataCorp, College Station, TX, 149 
USA).  150 
 151 
Study clearance and ethical considerations 152 
The KEMRI National Ethical Review Committee approved the study (SSC 2301). Informed 153 
consent was obtained from all parents/guardians before enrollment. 154 
 155 
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RESULTS 156 
During the study period, 1,014 neonates were admitted to Kilifi County Hospital, and the 157 
parents/guardians of 597 neonates gave consent for them to participate in the study (Figure 2). 158 
The median age of the participants was one day (IQR 0-3 days) and the median duration of 159 
hospital stay was 5 days (IQR 3-9 days). 160 
 161 
Of 597 who gave consent to participate, five parents/guardians withdrew consent and 23 162 
neonates had no swab collected. The prevalence of ESBL carriage at admission was 10% 163 
(59/569). From the 59 neonates with ESBL-E carriage at admission, there were 65 isolates 164 
consisting of 31 Klebsiella pneumoniae, 25 Escherichia coli, 8 Enterobacter cloacae and 1 165 
Klebsiella oxytoca. Multiple colonization, ie. colonization with two or more ESBL-E from one 166 
participant, was found in 6/59 neonates (10%). 167 
 168 
Among the 510 non-carriers on admission, 55% (283/510) acquired ESBL-E during their hospital 169 
stay. The incidence of ESBL-E acquisition was 21.4 (95% CI 19.0, 24.0) per 100 child days of 170 
observation, and the median time to acquisition among these patients was 3 (IQR 1-5) inpatient 171 
days (Figure 3). Nine neonates were diagnosed with ESBL-E bacteraemia during this study, all 172 
of whom had ESBL-E isolated from fecal carriage prior to or on the same day as blood was 173 
collected. 174 
 175 
Most ESBL-E isolates in the study were multi-drug resistant; resistance to chloramphenicol, 176 
trimethoprim-sulfamethoxazole, quinolones and gentamicin being common, none were resistant 177 
to imipenem and only 5% were resistant to amikacin (Table 1).  178 
 179 
Risk factors for ESBL-E carriage at admission 180 
 9 
In the univariable analysis, variables associated with prevalent ESBL-E carriage on admission 181 
were: being born at term (rather than premature), older infant age at admission, having fewer than 182 
eight people living in the same house, and hospital delivery, particularly by caesarean section 183 
(CS) (Table 2 and Supplementary Table S1). Babies born prematurely were more commonly 184 
admitted directly to the neonatal ward (107/157, 68%) than babies born at full term (114/410, 185 
28%; P-value<0.001). After adjusting for prematurity and place/mode of delivery, increasing infant 186 
age was positively associated (p<0.001) with ESBL-E carriage at admission, with odds ratios 1.72 187 
(95% CI 0.69 – 4.27) and 3.88 (95% CI 1.47 - 10.21) among neonates aged 1-2 days and 3-28 188 
days respectively, relative to the odds of ESBL carriage among neonates admitted on the day of 189 
birth. Being born at term was not associated with ESBL-E carriage after adjusting for the effect 190 
mediated through age on admission. We did not estimate an adjusted OR for place/mode of 191 
delivery and number of people in the same household since the associations were not confounded 192 
(Figure 1). 193 
 194 
Risk factors associated with acquisition of ESBL-E during hospitalization 195 
In the univariable analysis, hospital ward on admission, the number of neonates present in the 196 
hospital, the number of other neonates admitted in the same ward, and the number of known 197 
ESBL-E carriers were associated with incident acquisition of carriage (Table 3).  and 198 
Supplementary table S2). Both current number of known neonatal ESBL-E carriers and number 199 
of other neonates in the same ward were positively associated with carriage acquisition when 200 
simultaneously included in multivariable model (Table 4), and there was no interaction between 201 
these risk factors. In both the univariable and multivariable analyses, the number of neonates in 202 
the ward exhibited a threshold effect whereby there was a plateau effect in carriage acquisition 203 
beyond 10 patients per ward. Recorded antibiotic prescription, specifically use of third generation 204 
cephalosporins during the inpatient stay was not shown to be associated with ESBL-E acquisition.  205 
 206 
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DISCUSSION 207 
Our study reveals that among neonates admitted to a rural Kenyan hospital, 10% were already 208 
carriers of ESBL-E. Among those neonates who were not carriers at admission, 21.4% acquired 209 
ESBL-E carriage each day of admission; thus, more than half of the neonates were colonized with 210 
ESBL within the first three inpatient days.  211 
 212 
For babies coming in to hospital, the main risk factors for existing rectal carriage with ESBL-E 213 
were delivery in hospital via caesarean section and older infant age at admission. For those 214 
admitted without carriage of ESBL-E, the principal risk factors for acquisition in hospital were the 215 
number of other neonates in the ward and the number with ESBL-E carriage.  216 
Delivery through caesarean section has been reported to be a significant risk factor for prolonged 217 
faecal colonization with ESBL producing K. pneumoniae[16] and also a determinant of intestinal 218 
microflora early in life[17,18]. Mothers undergoing caesarean section are treated with antibiotics 219 
for surgical prophylaxis, sometimes extended to treatment of wound infections[19], which may 220 
select for antibiotic-resistant enteric bacteria. In Cambodia, young hospital-born infants were 221 
found to be at a greater risk of early colonization by third generation cephalosporins resistant 222 
gram-negative rods compared to infants born at home, a health centre or other locations and 223 
subsequently admitted to hospital[20].  In Madagascar, Herindrainy et al. reported that low birth 224 
weight, caesarean section and use of antibiotics by mothers at delivery were independently 225 
associated with neonatal acquisition of ESBL-E during the first month of life[21]. Hospital born 226 
infants through caesarean section delivery have been found to be at a higher risk of ESBL-E 227 
carriage in Lebanon[22]. 228 
The finding that babies coming from a large family of >8 household members were less likely to 229 
carry ESBL-E at admission was initially surprising. We speculate that these neonates may have 230 
a more diverse gut microbiome, which could be protective against acquisition of ESBL-E carriage. 231 
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Increased neonatal age at hospital admission was associated with a greater likelihood of ESBL-232 
E carriage, as expected, since older neonates have had more time to acquire carriage.  233 
Overall, we isolated ESBL-E from 10% of swabs within 48 hours of admission. In a cross-sectional 234 
ESBL-E carriage study done in a Tanzanian hospital, the overall neonatal prevalence of ESBL-E 235 
carriage was 25.4% [22]. Our findings suggest that some acquisition occurs before neonates 236 
come into the paediatric wards and we can speculate that this does not only come from their 237 
mothers but also from the procedures and settings of childbirth, particularly caesarian delivery. 238 
We did not collect data on ESBL-E carriage in mothers or maternal antibiotic use. 239 
 240 
Among neonates admitted without carriage, 55% acquired ESBL-E during hospitalization. An 241 
ESBL-E carriage study in a tertiary hospital in Rwanda among inpatients of all ages reported that 242 
55% of participants acquired ESBL-E carriage during hospitalization [23]. A study in Madagascar 243 
reported that 48% of pediatric non-carriers at admission acquired ESBL-E during hospitalization. 244 
[9]; while in a re-nutrition center in Niger, 94% of recovering malnourished children acquired 245 
ESBL-E during treatment with ceftriaxone, although only a few participants were sampled at 246 
discharge [25]. 247 
 248 
Our findings from the longitudinal study suggest that the greatest risk factors for ESBL-E 249 
acquisition in hospital were having increased numbers of existing ESBL-E carriers among the 250 
neonatal patients and a greater number of neonates admitted to the ward. We assume that 251 
increased numbers of ESBL-E carriers increase the opportunity for transmission. This finding 252 
corresponds with a prospective cohort study done in the general intensive care unit of a hospital 253 
in Greece; colonization pressure contributed significantly to acquisition of carriage of 254 
carbapenemase producing Klebsiella pneumoniae in hospital[24]. Intuitively, hospital crowding is 255 
expected to be associated with higher rates of ESBL-E transmission and our results support this. 256 
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However, our findings suggest a threshold effect where risk plateaued after admitting more than 257 
10-14 neonates in a ward, suggesting that transmission effects associated with crowding are 258 
complex. Restricting the number of neonatal admissions to the hospital is impractical, but this 259 
does justify allocating increased space to neonatal admissions. Fixed low healthcare staff 260 
numbers relative to numbers of patients, the cultural practice of mothers caring for each other’s 261 
babies on the ward, physical proximity of adjacent neonates, and shared hygiene facilities, may 262 
all contribute to acquisition of ESBL-E carriage by neonates in hospital. As well as direct 263 
transmission between babies on the ward, nosocomial carriage acquisition directly from the 264 
hospital environment is also possible. A study in Cambodia of transmission of third-generation 265 
cephalosporin-resistant Klebsiella pneumoniae isolates in a newly opened neonatal unit found 266 
that most clusters were likely to have been due to patient sources while 2 of 9 clusters could have 267 
been due to either an environmental or a patient source[25]. 268 
 269 
During the study period, nine neonates were diagnosed with ESBL-E bacteraemia. Nosocomial 270 
spread of ESBL-E carriage may result in outbreaks of ESBL-E bacteraemia in the hospital; such 271 
outbreaks have occurred in KCH in recent years [12], signifying the importance of awareness of 272 
ESBL-E carriage. There is potential for surveillance to help inform hospital infection control and 273 
to assist in averting such outbreaks. At KCH screening for carriage of ESBL-E among neonates 274 
is not routinely done, hand washing facilities frequently lack water supply, and there are no fully 275 
dedicated infection control staff..  In this rural setting, most mothers use reusable cloth diapers 276 
and use a shared ablution block in the hospital where they wash soiled nappies for reuse. 277 
 278 
Antibiotic use has been shown to affect the composition of gut microbiota and is associated with 279 
ESBL-E carriage and acquisition[9,16,17,24,26]. Antimicrobial stewardship services are used as 280 
part of hospital infection control services to reduce ESBL carriage in well-resourced hospitals. We 281 
were unable to detect antibiotic use as a risk factor for ESBL-E acquisition in our study. We 282 
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suspect that this is mainly attributed to the fact that 93% of our participants were given antibiotics 283 
during their hospital stay and we were therefore underpowered to observe any differences 284 
(Supplementary table S2). 285 
 286 
We did not collect data from babies after they were discharged from hospital, but patients 287 
discharged with ESBL-E carriage have been shown to spread these ESBL-E within family units 288 
and close contacts[16,27]. In a prospective cohort study of infants and their families in Norway, 289 
the median carriage duration among infants discharged with carriage of ESBL-producing 290 
Klebsiella pneumoniae after a hospital outbreak was 12.5 months[16]. Another study reported the 291 
median time to ESBL-E clearance post discharge to be 6.6 months[30] from carriage data of 292 
readmitted adult and paediatric patients. If carriage of ESBL-E persists and intra-household 293 
transmission occurs, discharged patients may act as reservoirs of ESBL-E in the community. 294 
 295 
Being a hospital-based study, focusing on sick newborns, our estimates of ESBL-E prevalence at 296 
admission cannot be generalized to community prevalence. It is theoretically possible that low-297 
level ESBL-E carriage was more prevalent at admission than we were able to determine; below 298 
detection rate by culture methods, but then amplified by selection pressure from the use of 299 
antibiotics in hospital until detectable. We also were only able to recruit 68% of eligible neonates 300 
limiting the generalizability of our findings (Supplementary table S13). Of note, significantly more 301 
parents/guardians of older neonates, and neonates born in hospital by caesarean section, 302 
declined to participate in the study suggesting that our estimate of prevalence of ESBL-E carriage 303 
at admission is likely to be an underestimate. Our prevalence and incidence estimates may also 304 
be underestimates since stool culture may be more sensitive than rectal swab culture, a single 305 
sample is less sensitive than multiple samples for culture s and some Enterobacter spp, which 306 
are known to produce AmpC beta-lactamases, may have tested falsely-negative for ESBL by the 307 
phenotypic method used.  We did not find any carbapenem resistant Enterobacterales (CRE) in 308 
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this study, but it is known that such isolates are present in Kenya[28,29], and globally are on the 309 
rise. Use of central quality assured microbiology laboratories in surveillance for ESBL-E carriage 310 
could therefore be expected to have the added benefit of an early warning system for the 311 
introduction of CRE carriage. 312 
 313 
In conclusion, our findings reveal a high incidence of ESBL-E colonization among hospitalized 314 
neonates, which is endemic in this setting. Further work to investigate the association between 315 
ESBL-E acquisition and both caesarean section delivery and crowding, perhaps including 316 
restrictions on room capacity, and more deliberate cohorting of older neonates and those born in 317 
hospital through caesarean section is needed. Given the link between ESBL-E carriage and 318 
outbreaks of potentially fatal ESBL-E infection, our data emphasize the importance of routine 319 
surveillance and hospital infection control. 320 
321 
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